Dataset Information


Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

ABSTRACT: BACKGROUND:The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 ?g twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment. The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT). METHODS:Patients ?40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity <70 % and FEV1??30 % but <80 % predicted normal) were randomised (ACLIFORM: 2:2:2:2:1; AUGMENT: 1:1:1:1:1) to twice-daily aclidinium/formoterol 400/12 ?g or 400/6 ?g, aclidinium 400 ?g, formoterol 12 ?g or placebo via Genuair™/Pressair®. Dyspnoea (Transition Dyspnoea Index; TDI), daily symptoms (EXAcerbations of Chronic pulmonary disease Tool [EXACT]-Respiratory Symptoms [E-RS] questionnaire), night-time and early-morning symptoms, exacerbations (Healthcare Resource Utilisation [HCRU] and EXACT definitions) and relief-medication use were assessed. RESULTS:The pooled intent-to-treat population included 3394 patients. Aclidinium/formoterol 400/12 ?g significantly improved TDI focal score versus placebo and both monotherapies at Week 24 (all p?


PROVIDER: S-EPMC4531806 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6396834 | BioStudies
2017-01-01 | S-EPMC5434772 | BioStudies
2017-01-01 | S-EPMC5450266 | BioStudies
1000-01-01 | S-EPMC5026215 | BioStudies
2014-01-01 | S-EPMC4273456 | BioStudies
2014-01-01 | S-EPMC4213545 | BioStudies
2016-01-01 | S-EPMC4833795 | BioStudies
2019-01-01 | S-EPMC6902852 | BioStudies
2016-01-01 | S-EPMC5174811 | BioStudies
2016-01-01 | S-EPMC5152596 | BioStudies